Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

RPRX - Royalty Pharma plc So'nggi Yangiliklar | Finranks

Home

RPRX

(RPRX)

NMS – Real vaqt narxi. Valyuta: USD

46.35

-0.59 (-1.26%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

46.35

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 6:10 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma.

Royalty Pharma Announces Expansion of Leadership Team

Royalty Pharma Announces Expansion of Leadership Team

Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments

Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking.

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zymeworks Inc. (Nasdaq: ZYME) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne).

Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference

Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET.

Royalty Pharma: 2025 Financial Performance And Strategic Outlook

Royalty Pharma: 2025 Financial Performance And Strategic Outlook

Royalty Pharma delivered robust FY25 results, with double-digit growth in Royalty Receipts and Portfolio Receipts, and disciplined capital deployment. RPRX expanded its portfolio through $2.6B in new royalty transactions, $1.2B in share repurchases, and a 7% dividend increase entering 2026. Synthetic royalties emerged as a major growth engine, surpassing traditional royalties in announced transaction value and offering structural advantages for biopharma funding.

Videolar

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

President Trump demands drugmakers slash prices within 60 days

Press-relizlar

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma.

Royalty Pharma Announces Expansion of Leadership Team

Royalty Pharma Announces Expansion of Leadership Team

Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking.

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zymeworks Inc. (Nasdaq: ZYME) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne).